UG Healthcare Receives SGX Listing and Quotation Notice for New Share Schemes

Key Developments in the 2024 Unigloves Employee Share Option Scheme and Performance Share Plan

UG Healthcare Corporation Limited (“UG Healthcare” or the “Company”) has announced a significant milestone that could impact its share price and long-term shareholder value. The Company recently received the Listing and Quotation Notice (LQN) from the Singapore Exchange Securities Trading Limited (SGX-ST) for the listing and quotation of new ordinary shares to be issued under two major share incentive schemes:

• 2024 Unigloves Employee Share Option Scheme (ESOS)
• 2024 Unigloves Performance Share Plan (PSP)

Highlights of the Announcement

• Shareholders approved the adoption of both the 2024 Unigloves ESOS and 2024 Unigloves PSP at the General Meeting held on 29 October 2024.
• On 9 April 2026, the Company received an LQN from SGX-ST, enabling the future listing and quotation of new shares to be issued under these schemes, subject to compliance with SGX-ST listing requirements.
• The aggregate number of new shares issued under the ESOS, PSP, and all other share schemes in force must not exceed 15% of the total issued share capital (excluding treasury shares and subsidiary holdings) on the day immediately preceding the grant date.
• The LQN is not an endorsement of the merits of the share schemes, new shares, or the Company by SGX-ST.

Implications and Key Information for Shareholders

• Potential Dilution: The approval allows the Company to issue up to 15% new shares under these schemes, which may dilute existing shareholders’ percentage of ownership. Investors should monitor announcements on the actual grants and issuance for more precise impacts.
• Employee Alignment: The introduction of the ESOS and PSP is designed to incentivize and retain key employees, aligning their interests with shareholders and potentially improving company performance and share value over time.
• Future Announcements Expected: The Company has stated it will provide further updates concerning the ESOS and PSP as required, which could include detailed terms, grant dates, and quantum of shares to be issued.
• Market Sensitivity: The potential issuance of up to 15% of new shares could be price-sensitive, especially at the time of grant or award, as it may impact supply and demand dynamics for UG Healthcare shares.

Corporate Governance and Sponsor Review

• This announcement was reviewed by the Company’s Sponsor, SAC Capital Private Limited.
• The SGX-ST has not examined or approved the content of the announcement and assumes no responsibility for its accuracy.

Conclusion

The receipt of the LQN for the 2024 Unigloves ESOS and PSP marks an important development for UG Healthcare, potentially impacting the Company’s capital structure and share price. Shareholders are advised to closely monitor forthcoming detailed disclosures regarding the implementation of these schemes, as the actual size and timing of share issuance under these plans could influence the market value and shareholder returns.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult with a qualified financial advisor before making investment decisions. The information herein is based on the most recent company announcement and may be subject to change.

View UGHealthcare Historical chart here